Publications by authors named "Bob Salim"

Claim this Profile
Z
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study.
Santiago Escrivá-de-Romani, Juan M Cejalvo, Emilio Alba, Jennifer Friedmann, Álvaro Rodríguez-Lescure, Bob Salim

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.
Philip J Mease, Scott Stryker, Mei Liu, Bob Salim, Sabrina Rebello

Arthritis Res Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Paul Nghiem, Shailender Bhatia, Evan J Lipson, William H Sharfman, Ragini R Kudchadkar, Bob Salim

J Immunother Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice.
Gary Craig, Keith Knapp, Bob Salim, Shalini V Mohan, Margaret Michalska

Rheumatol Ther· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.
Nina Bhardwaj, Philip A Friedlander, Anna C Pavlick, Marc S Ernstoff, Brian R Gastman, Bob A Salim

Nat Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
Paul Nghiem, Shailender Bhatia, Evan J Lipson, William H Sharfman, Ragini R Kudchadkar, Bob Salim

J Clin Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study.
Cynthia J Larmore, Natalie N Boytsov, Carol L Gaich, Xiang Zhang, Andre B Araujo, Bob A Salim

Rheumatol Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry.
Dimitrios A Pappas, Joel M Kremer, Jenny Griffith, George Reed, Bob Salim

Rheumatol Ther· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis